We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues Another Warning to AstraZeneca for Crestor Promotion
FDA Issues Another Warning to AstraZeneca for Crestor Promotion
April 4, 2005
The FDA’s Division of Drug Marketing, Advertising, and Communications (DDMAC) has issued AstraZeneca its second untitled letter in four months regarding promotional activities for the company’s cholesterol-lowering drug Crestor.